Elite Pharmaceuticals Signs License Agreement With Epic Pharma
Elite Pharmaceuticals signs a manufacturing and license agreement with Epic Pharma for 12 generic drug products.
Elite Pharmaceuticals, a company that specializes in the development of oral controlled-release products, has signed a manufacturing and license agreement with Epic Pharm, a developer and manufacturer of generic prescription drugs. Under the terms of the agreement, Epic will have the right to manufacture, market, and sell 12 generic drug products owned by Elite in the United States and Puerto Rico. Of the 12 products, Epic will have the exclusive right to market six products and the nonexclusive right to market six additional products. Epic is also responsible for all regulatory and pharmacovigilance matters related to the products and for all costs related to the site transfer for all products. Elite will receive a license fee and milestone payments. The term of the license agreement is five years and may be extended for an additional five years upon mutual agreement.
Source: Elite Pharmaceuticals
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
